Drug profile

The FDA adverse-event record for Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
88.2%
death-coded share
Cattle
most-reported species
14
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
15
Deaths Reported
88.2%
Death Rate

Active Ingredients

Clostridium ChauvoeiClostridium NovyiClostridium Perfringens Type C Bacterin ToxoidClostridium Perfringens Type D Bacterin ToxoidClostridium SepticumClostridium SordelliiHaemophilus Somnus Bacterin Toxoid

Administration Routes

SubcutaneousUnknown

Species Affected

Cattle 17

Most Affected Breeds

Cattle (other) 10
Aberdeen Angus 5
Crossbred Bovine/Cattle 1
Cattle (unknown) 1

Most Reported Reactions

Death 14
Lack of efficacy - NOS 8
Lack of efficacy (bacteria) - NOS 4
Necropsy performed 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Open mouth breathing 1
Depression 1
Panting 1
Recumbency 1
Foam in the nose 1
NT - Abnormal necropsy finding NOS 1
Lack of efficacy (bacteria NOS) 1

Outcome Breakdown

Died
15 (44.1%)
Recovered/Normal
11 (32.4%)
Outcome Unknown
5 (14.7%)
Ongoing
2 (5.9%)
Recovered with Sequela
1 (2.9%)

Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid Adverse Event Insights

17 reports name Clostridium Chauvoei + Clostridium Novyi + Clostridium Perfringens Type C Bacterin Toxoid + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii + Haemophilus Somnus Bacterin Toxoid; 15 recorded a death outcome (88.2% of reported events, not a population-level mortality rate). Active ingredients: Clostridium Chauvoei, Clostridium Novyi, Clostridium Perfringens Type C Bacterin Toxoid, Clostridium Perfringens Type D Bacterin Toxoid, Clostridium Septicum. Administration routes: Subcutaneous, Unknown.

By species: Cattle (17 reports). By breed: Cattle (other) (10), Aberdeen Angus (5), Crossbred Bovine/Cattle (1).

Leading clinical signs: Death (14), Lack of efficacy - NOS (8), Lack of efficacy (bacteria) - NOS (4), Necropsy performed (3). Outcome, 34 coded reports: Died leads at 44.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.